newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeutics Inc. ("PBT") has entered into a definitive agreement to